Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A hotspot phosphorylation site on SHP2 drives oncoprotein activation and drug resistance.

Nature communications - 3 Mar 2026

Karunaraj Prashath, Scheele Remkes, Wells Malcolm L, Rathod Ruchita, Gokulu Ipek S, Abrahamson Sophia R, Taylor Lila, Chowdhury Lamia, Kazmi Abiha, Song Weixiao, Hornbeck Peter V, Li Jing, Glasgow Anum, Vasan Neil

Abstract excerpt

SHP2 is a phosphatase and a critical mediator of receptor tyrosine kinase (RTK)-driven RAS/mitogen-activated protein kinase (MAPK) signaling. Despite promising preclinical data, SHP2 inhibitors have shown minimal clinical efficacy, with no defined clinical mechanisms of primary resistance. Here, we elucidate phosphorylation of SHP2 at tyrosine 62 (pY62) as a hotspot phosphorylation site in the proteome and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Signaling System

Share to Mutation

Share to Phosphorylation

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 11

Share to Receptor Protein-Tyrosine Kinases

Share to src-Family Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 41775683
DOI: 10.1038/s41467-026-70060-8
PMCID: PMC13066003

Genes

SRC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A hotspot phosphorylation site on SHP2 drives oncoprotein activation and drug resistance.PMID 41775683Read ↗

A Hotspot Phosphorylation Site on SHP2 Drives Oncoprotein Activation and Drug ResistanceSemantic proximity Read ↗

A Hotspot Phosphorylation Site on SHP2 Drives Oncoprotein Activation and Drug ResistanceSemantic proximity Read ↗

Phosphorylation of SHP2 at Tyr62 Enables Acquired Resistance to SHP2 Allosteric Inhibitors in FLT3-ITD-Driven AML.Semantic proximity Read ↗

The pathogenic T42A mutation in SHP2 rewires the interaction specificity of its N-terminal regulatory domain.Semantic proximity Read ↗

The pathogenic T42A mutation in SHP2 rewires the interaction specificity of its N-terminal regulatory domainSemantic proximity Read ↗

Inhibition of SHP2 as an approach to block RAS-driven cancers.Semantic proximity Read ↗

Targeting SHP2 phosphatase in hematological malignancies.Semantic proximity Read ↗

Targeting SHP2 Cryptic Allosteric Sites for Effective Cancer Therapy.Semantic proximity Read ↗

Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application.Semantic proximity Read ↗

Targeting Oncogenic Src Homology 2 Domain-Containing Phosphatase 2 (SHP2) by Inhibiting Its Protein-Protein Interactions.Semantic proximity Read ↗

Strategies to overcome drug resistance using SHP2 inhibitorsSemantic proximity Read ↗

Targeting Oncogenic Src Homology 2 Domain-Containing Phosphatase 2 (SHP2) by Inhibiting its Protein-Protein InteractionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.